Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Liver Diseases

Free Subscription Articles published in J Gastroenterol Hepatol Retrieve available abstracts of 151 articles: HTML format

Single Articles

November 2021
1. GAZELAKIS K, Mendis S, Wang S, Wong S, et al
   Hepatobiliary and Pancreatic: Liver lesions in cirrhosis: When to biopsy?
   J Gastroenterol Hepatol. 2021 Nov 22. doi: 10.1111/jgh.15735.
   PubMed    
   
   
   
2. KIM BH, Yu SJ, Kang W, Cho SB, et al
   Expert Consensus on the Management of Adverse Events in Patients Receiving Lenvatinib for Hepatocellular Carcinoma.
   J Gastroenterol Hepatol. 2021 Nov 1. doi: 10.1111/jgh.15727.
   PubMed     Abstract available
   
   
   October 2021
3. LE TV, Dinh NBT, Dang MT, Phan NCL, et al
   THE EFFECTS OF AUTOPHAGY INHIBITION BY CHLOROQUINE ON HEPATIC STELLATE CELL ACTIVATION IN CCl4 -INDUCED ACUTE LIVER INJURY MOUSE MODEL.
   J Gastroenterol Hepatol. 2021 Oct 28. doi: 10.1111/jgh.15726.
   PubMed     Abstract available
   
   
   
4. CHANG WI, Kim BH, Kim YJ, Yoon JH, et al
   The role of radiotherapy in Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma treated with sorafenib.
   J Gastroenterol Hepatol. 2021 Oct 24. doi: 10.1111/jgh.15722.
   PubMed     Abstract available
   
   
   
5. NAKATSU G
   Toward a postbiotic era of microbiome science: opportunities to advance immunotherapies for hepatocellular carcinoma.
   J Gastroenterol Hepatol. 2021 Oct 19. doi: 10.1111/jgh.15715.
   PubMed     Abstract available
   
   
   
6. HUO TI, Ho SY, Liao JI
   Improved patient survival in hepatitis C virus-related hepatocellular carcinoma: Do direct-acting antivirals play a role?
   J Gastroenterol Hepatol. 2021 Oct 15. doi: 10.1111/jgh.15707.
   PubMed    
   
   
   
7. YIM HJ, Kim W, Ahn SH, Jung YK, et al
   Besifovir therapy improves hepatic histology and reduces covalently closed circular DNA in chronic hepatitis B patients.
   J Gastroenterol Hepatol. 2021 Oct 15. doi: 10.1111/jgh.15710.
   PubMed     Abstract available
   
   
   
8. OGAWA E, Kawano A, Ooho A, Furusyo N, et al
   Long-term hepatic function of patients with compensated cirrhosis following successful direct-acting antiviral treatment for HCV infection.
   J Gastroenterol Hepatol. 2021 Oct 7. doi: 10.1111/jgh.15703.
   PubMed     Abstract available
   
   
   September 2021
9. LI R, Ong Q, Wong CC, Chu ES, et al
   O-GlcNAcylation inhibits hepatic stellate cell activation.
   J Gastroenterol Hepatol. 2021 Sep 21. doi: 10.1111/jgh.15690.
   PubMed     Abstract available
   
   
   
10. LOCKART I, Hajarizadeh B, Buckley N, Davison S, et al
    All cause hepatocellular carcinoma survival in the era of direct-acting antiviral therapy.
    J Gastroenterol Hepatol. 2021 Sep 14. doi: 10.1111/jgh.15687.
    PubMed     Abstract available
    
    
    
11. YADA S, Sasaki S, Tokuno K, Yamashita Y, et al
    Hepatobiliary and Pancreatic: Extramammary Paget disease of the esophagus.
    J Gastroenterol Hepatol. 2021 Sep 2. doi: 10.1111/jgh.15665.
    PubMed    
    
    
    August 2021
12. ZHAO D, Xia L, Geng W, Xu D, et al
    Metformin suppresses IL-22 induced hepatocellular carcinoma by upregulating Hippo signaling pathway.
    J Gastroenterol Hepatol. 2021 Aug 25. doi: 10.1111/jgh.15674.
    PubMed     Abstract available
    
    
    
13. EMORI T, Nuta J, Kawaji Y, Tamura T, et al
    Value of contrast-enhanced harmonic endoscopic ultrasound for diagnosing hepatic metastases of pancreatic cancer: a prospective study.
    J Gastroenterol Hepatol. 2021 Aug 16. doi: 10.1111/jgh.15661.
    PubMed     Abstract available
    
    
    
14. OGAWA E, Nakamuta M, Furusyo N, Kajiwara E, et al
    Long-term assessment of recurrence of hepatocellular carcinoma in patients with chronic hepatitis C after viral cure by DAAs.
    J Gastroenterol Hepatol. 2021 Aug 9. doi: 10.1111/jgh.15659.
    PubMed     Abstract available
    
    
    
15. UENO M, Mano T, Kayahara T, Mizuno M, et al
    Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding: It's time to step forward.
    J Gastroenterol Hepatol. 2021 Aug 8. doi: 10.1111/jgh.15652.
    PubMed    
    
    
    
16. CHEN M, Hu G, Zhou X, Peng Z, et al
    Hsa_circ_0016788 regulates glycolysis and proliferation via miR-506-3p/PARP14 axis of hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2021 Aug 2. doi: 10.1111/jgh.15635.
    PubMed     Abstract available
    
    
    July 2021
17. MAK J, Chan SM, Siu B, Lai J, et al
    Hepatobiliary and Pancreatic: A tree in the liver.
    J Gastroenterol Hepatol. 2021 Jul 27. doi: 10.1111/jgh.15623.
    PubMed    
    
    
    
18. ATTEBERRY P, Biederman B, Jesudian A, Lucero C, et al
    Mortality, Sepsis, and Organ Failure in Hospitalized Patients with Cirrhosis Vary by Type of Infection.
    J Gastroenterol Hepatol. 2021 Jul 22. doi: 10.1111/jgh.15633.
    PubMed     Abstract available
    
    
    
19. SHI M, Sheng L, Lian M, Miao Q, et al
    Efficacy and safety of rifampicin in patients with persistent hepatocellular secretory failure.
    J Gastroenterol Hepatol. 2021 Jul 19. doi: 10.1111/jgh.15629.
    PubMed     Abstract available
    
    
    
20. WU L, Huang XQ, Li N, Xie C, et al
    An MRI Modality for Non-invasively Distinguishing Progression of Liver Fibrosis by Visualizing Hepatic Platelet-Derived Growth Factor Receptor-Beta Expression in Mice.
    J Gastroenterol Hepatol. 2021 Jul 19. doi: 10.1111/jgh.15628.
    PubMed     Abstract available
    
    
    
21. KRIGE J, Jonas E, Spence R, Bernon M, et al
    Letter to the editor: The complexities of predicting outcome in cirrhotic patients with acute variceal bleeding.
    J Gastroenterol Hepatol. 2021 Jul 12. doi: 10.1111/jgh.15622.
    PubMed    
    
    
    
22. ITO T, Hanafusa N, Soneda N, Isoai A, et al
    Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) against cirrhotic ascites in comparison with malignancy-related ascites.
    J Gastroenterol Hepatol. 2021 Jul 11. doi: 10.1111/jgh.15620.
    PubMed     Abstract available
    
    
    June 2021
23. COUPER MR, Chennapragada M, Magoffin A
    Hepatobiliary and Pancreatic: A rare peribiliary lesion.
    J Gastroenterol Hepatol. 2021 Jun 29. doi: 10.1111/jgh.15556.
    PubMed    
    
    
    
24. ZULLO A, Soncini M, Bucci C, Marmo R, et al
    Clinical outcomes in cirrhotics with variceal or nonvariceal gastrointestinal bleeding: a prospective, multicenter cohort study.
    J Gastroenterol Hepatol. 2021 Jun 29. doi: 10.1111/jgh.15601.
    PubMed     Abstract available
    
    
    
25. HO SY, Liu PH, Hsu CY, Ko CC, et al
    Tumor burden score as a new prognostic marker for patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
    J Gastroenterol Hepatol. 2021 Jun 22. doi: 10.1111/jgh.15593.
    PubMed     Abstract available
    
    
    
26. PHRUEKSOTSAI S, Pinyopornpanish K, Euathrongchit J, Leerapun A, et al
    Dapagliflozin reduces hepatic and visceral fat in type-2 diabetes patients with non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2021 Jun 15. doi: 10.1111/jgh.15580.
    PubMed     Abstract available
    
    
    
27. FAJARDO J, Nunez E, Szafranska J, Poca M, et al
    We report a patient who presented intrahepatic cholangitis and cholecystitis after SARS-CoV-2 infection.
    J Gastroenterol Hepatol. 2021 Jun 9. doi: 10.1111/jgh.15537.
    PubMed    
    
    
    
28. CHUN HS, Lee JS, Lee HW, Kim BK, et al
    Association between the severity of liver fibrosis and cardiovascular outcomes in patients with type 2 diabetes.
    J Gastroenterol Hepatol. 2021;36:1703-1713.
    PubMed     Abstract available
    
    
    
29. HASSANI ZADEH S, Mansoori A, Hosseinzadeh M
    Relationship between dietary patterns and non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2021;36:1470-1478.
    PubMed     Abstract available
    
    
    
30. AHADI M, Molooghi K, Masoudifar N, Namdar AB, et al
    A review of non-alcoholic fatty liver disease in non-obese and lean individuals.
    J Gastroenterol Hepatol. 2021;36:1497-1507.
    PubMed     Abstract available
    
    
    
31. RHODES FA, Trembling P, Panovska-Griffiths J, Tanwar S, et al
    Systematic review: Investigating the prognostic performance of four non-invasive tests in alcohol-related liver disease.
    J Gastroenterol Hepatol. 2021;36:1435-1449.
    PubMed     Abstract available
    
    
    
32. LV T, Chen S, Li M, Zhang D, et al
    Regional variation and temporal trend of primary biliary cholangitis epidemiology: A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2021;36:1423-1434.
    PubMed     Abstract available
    
    
    
33. LIU D, Shen Y, Zhang R, Xun J, et al
    Prevalence and risk factors of metabolic associated fatty liver disease among people living with HIV in China.
    J Gastroenterol Hepatol. 2021;36:1670-1678.
    PubMed     Abstract available
    
    
    
34. HUANG Y, Huang F, Yang L, Hu W, et al
    Development and validation of a radiomics signature as a non-invasive complementary predictor of gastroesophageal varices and high-risk varices in compensated advanced chronic liver disease: A multicenter study.
    J Gastroenterol Hepatol. 2021;36:1562-1570.
    PubMed     Abstract available
    
    
    May 2021
35. ZHOU J, Wang C, Chen Z
    Hepatobiliary and Pancreatic: Castleman disease of the pancreas diagnosed by endoscopic ultrasound.
    J Gastroenterol Hepatol. 2021 May 31. doi: 10.1111/jgh.15520.
    PubMed    
    
    
    
36. KANEKO S, Kurosaki M, Inada K, Kirino S, et al
    Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients.
    J Gastroenterol Hepatol. 2021 May 31. doi: 10.1111/jgh.15563.
    PubMed     Abstract available
    
    
    
37. AGARWAL S, Sharma S, Kumar M, Venishetty S, et al
    Development of a machine learning model to predict bleed in esophageal varices in compensated advanced chronic liver disease: A proof of concept.
    J Gastroenterol Hepatol. 2021 May 28. doi: 10.1111/jgh.15560.
    PubMed     Abstract available
    
    
    
38. MA HL, Chen SD, Zheng KI, Yu Y, et al
    The TA allele of rs2070673 in the CYP2E1 gene is associated with lobular inflammation and nonalcoholic steatohepatitis in patients with biopsy-proven nonalcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2021 May 24. doi: 10.1111/jgh.15554.
    PubMed     Abstract available
    
    
    
39. TAK KY, Jang B, Lee SK, Nam HC, et al
    The prognostic role of M2BPGi compared with the HAP score in hepatocellular carcinoma patients receiving transarterial treatment.
    J Gastroenterol Hepatol. 2021 May 24. doi: 10.1111/jgh.15553.
    PubMed     Abstract available
    
    
    
40. ZHAO JA, Nie W, Dong L, Liu W, et al
    A curcumin analogue GL63 inhibits the malignant behaviors of hepatocellular carcinoma by inactivating the JAK2/STAT3 signaling pathway via the circZNF83/miR-324-5p/CDK16 axis.
    J Gastroenterol Hepatol. 2021 May 12. doi: 10.1111/jgh.15545.
    PubMed     Abstract available
    
    
    
41. CHANG H, Li J, Luo Y, Wu B, et al
    TFB2M activates aerobic glycolysis in hepatocellular carcinoma cells through the NAD(+) /SIRT3/HIF-1alpha signaling.
    J Gastroenterol Hepatol. 2021 May 12. doi: 10.1111/jgh.15548.
    PubMed     Abstract available
    
    
    
42. YANG C, Liu J, Shi Q, Huang S, et al
    Effect of splenectomy on the outcomes in patients with cirrhosis receiving transjugular intrahepatic portosystemic shunt.
    J Gastroenterol Hepatol. 2021 May 11. doi: 10.1111/jgh.15543.
    PubMed     Abstract available
    
    
    
43. XIE JM, Liu JH, Sun YH, Li W, et al
    Hepatobiliary and Pancreatic: Endoscopic resection of biliary ductal tumour.
    J Gastroenterol Hepatol. 2021 May 9. doi: 10.1111/jgh.15518.
    PubMed    
    
    
    
44. HSU WF, Tsai PC, Chen CY, Tseng KC, et al
    Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (T-COACH).
    J Gastroenterol Hepatol. 2021 May 7. doi: 10.1111/jgh.15538.
    PubMed     Abstract available
    
    
    
45. CHEN Z, Jiang H, Wang Y, Liang R, et al
    Three-day Postoperative Antibiotics Reduces Post-hepatectomy Infection Rate in HBV-related Hepatocellular Carcinoma.
    J Gastroenterol Hepatol. 2021 May 4. doi: 10.1111/jgh.15528.
    PubMed     Abstract available
    
    
    
46. ANAND A, Elhence A, Vaishnav M, Singh AA, et al
    FibroScan-aspartate aminotransferase score in an Asian cohort of non-alcoholic fatty liver disease and its utility in predicting histological resolution with bariatric surgery.
    J Gastroenterol Hepatol. 2021;36:1309-1316.
    PubMed     Abstract available
    
    
    
47. LI X, Qin P, Cao L, Lou Y, et al
    Dose-response association of the ZJU index and fatty liver disease risk: A large cohort in China.
    J Gastroenterol Hepatol. 2021;36:1326-1333.
    PubMed     Abstract available
    
    
    
48. TANDON R, Froghi S
    Artificial liver support systems.
    J Gastroenterol Hepatol. 2021;36:1164-1179.
    PubMed     Abstract available
    
    
    April 2021
49. PUDIPEDDI A, Han J, Leong R
    Hepatobiliary and Pancreatic: Right upper quadrant pain and positive Murphy's sign.
    J Gastroenterol Hepatol. 2021 Apr 29. doi: 10.1111/jgh.15510.
    PubMed    
    
    
    
50. KAPURIA D, Bollipo S, Rabiee A, Ben-Yakov G, et al
    Roadmap to resuming care for liver diseases after coronavirus disease-2019.
    J Gastroenterol Hepatol. 2021;36:885-892.
    PubMed     Abstract available
    
    
    
51. CHRYSAVGIS L, Papatheodoridi AM, Chatzigeorgiou A, Cholongitas E, et al
    The impact of sodium glucose co-transporter 2 inhibitors on non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2021;36:893-909.
    PubMed     Abstract available
    
    
    
52. SHIGEFUKU R, Iwasa M, Eguchi A, Tamai Y, et al
    Serum copeptin level is a biomarker associated with ascites retention and the formation of a portosystemic shunt in chronic liver disease.
    J Gastroenterol Hepatol. 2021;36:1006-1014.
    PubMed     Abstract available
    
    
    March 2021
53. IWAKI M, Kessoku T, Ozaki A, Kasai Y, et al
    Gut microbiota composition associated with hepatic fibrosis in non-obese patients with non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2021 Mar 11. doi: 10.1111/jgh.15487.
    PubMed     Abstract available
    
    
    
54. SHARMA C, Cococcia S, Ellis N, Parkes J, et al
    Systematic review: Accuracy of The Enhanced Liver Fibrosis Test for diagnosing advanced liver fibrosis and cirrhosis.
    J Gastroenterol Hepatol. 2021 Mar 5. doi: 10.1111/jgh.15482.
    PubMed     Abstract available
    
    
    
55. MOU H, Yang QA, Yu L, Wang T, et al
    PD-L1 expression in hepatocellular carcinoma and its correlation with clinicopathological characteristics.
    J Gastroenterol Hepatol. 2021 Mar 3. doi: 10.1111/jgh.15475.
    PubMed     Abstract available
    
    
    
56. SATO M, Tateishi R, Yatomi Y, Koike K, et al
    Artificial intelligence in the diagnosis and management of hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2021;36:551-560.
    PubMed     Abstract available
    
    
    
57. SU TH, Wu CH, Kao JH
    Artificial intelligence in precision medicine in hepatology.
    J Gastroenterol Hepatol. 2021;36:569-580.
    PubMed     Abstract available
    
    
    
58. SUNG YS, Park B, Park HJ, Lee SS, et al
    Radiomics and deep learning in liver diseases.
    J Gastroenterol Hepatol. 2021;36:561-568.
    PubMed     Abstract available
    
    
    
59. WONG GL, Yuen PC, Ma AJ, Chan AW, et al
    Artificial intelligence in prediction of non-alcoholic fatty liver disease and fibrosis.
    J Gastroenterol Hepatol. 2021;36:543-550.
    PubMed     Abstract available
    
    
    
60. LEE HW, Sung JJY, Ahn SH
    Artificial intelligence in liver disease.
    J Gastroenterol Hepatol. 2021;36:539-542.
    PubMed     Abstract available
    
    
    February 2021
61. WEST J, Gow PJ, Testro A, Chapman B, et al
    Exercise physiology in cirrhosis and the potential benefits of exercise interventions - a review.
    J Gastroenterol Hepatol. 2021 Feb 27. doi: 10.1111/jgh.15474.
    PubMed     Abstract available
    
    
    
62. HEO YJ, Choi SE, Lee N, Jeon JY, et al
    Visfatin exacerbates hepatic inflammation and fibrosis in a methionine-choline-deficient diet mouse model.
    J Gastroenterol Hepatol. 2021 Feb 18. doi: 10.1111/jgh.15465.
    PubMed     Abstract available
    
    
    
63. JEONG Y, Lee KJ, Lee SJ, Shin YM, et al
    Radiofrequency ablation versus stereotactic body radiation therapy for small (
    J Gastroenterol Hepatol. 2021 Feb 17. doi: 10.1111/jgh.15442.
    PubMed     Abstract available
    
    
    
64. WU Y, Xiang Q, Lv X, Xiang X, et al
    C2orf40 inhibits hepatocellular carcinoma through UBR5-dependent or p53-independent mechanisms.
    J Gastroenterol Hepatol. 2021 Feb 12. doi: 10.1111/jgh.15441.
    PubMed     Abstract available
    
    
    
65. JIA Z, Zhang H, Li N
    Evaluation of clinical outcomes of radiofrequency ablation and surgical resection for hepatocellular carcinoma conforming to the Milan criteria: A systematic review and meta-analysis of recent randomized controlled trials.
    J Gastroenterol Hepatol. 2021 Feb 10. doi: 10.1111/jgh.15440.
    PubMed     Abstract available
    
    
    
66. KIM JH, Park SW, Jung JH, Park DH, et al
    Bedside Risk-Scoring Model for Predicting 6-Week Mortality in Cirrhotic Patients Undergoing Endoscopic Band Ligation for Acute Variceal Bleeding.
    J Gastroenterol Hepatol. 2021 Feb 4. doi: 10.1111/jgh.15426.
    PubMed     Abstract available
    
    
    
67. VADARLIS A, Antza C, Bakaloudi DR, Doundoulakis I, et al
    Systematic review with meta-analysis: The effect of vitamin E supplementation in adult patients with non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2021;36:311-319.
    PubMed     Abstract available
    
    
    January 2021
68. TENG CF, Wang T, Shih FY, Shyu WC, et al
    Therapeutic Efficacy of Dendritic Cell Vaccine Combined with Programmed Death 1 Inhibitor for Hepatocellular Carcinoma.
    J Gastroenterol Hepatol. 2021 Jan 19. doi: 10.1111/jgh.15398.
    PubMed     Abstract available
    
    
    
69. YOO BH, Kim SH, Baek YJ, Yeom JS, et al
    Hepatobiliary and Pancreatic: Liver abscess not responding to drainage and antibiotics.
    J Gastroenterol Hepatol. 2021 Jan 17. doi: 10.1111/jgh.15383.
    PubMed    
    
    
    
70. DING ZN, Dong ZR, Chen ZQ, Yang YF, et al
    Effects of HIF-1alpha and HIF-2alpha overexpression on hepatocellular carcinoma survival: A systematic review with meta-analysis.
    J Gastroenterol Hepatol. 2021 Jan 4. doi: 10.1111/jgh.15395.
    PubMed     Abstract available
    
    
    
71. YI F, Guo X, Wang L, Xu X, et al
    Spontaneous splenorenal shunt may decrease the long-term survival of liver cirrhosis by compromising liver volume.
    J Gastroenterol Hepatol. 2021 Jan 3. doi: 10.1111/jgh.15386.
    PubMed     Abstract available
    
    
    
72. GAO F, Zheng KI, Wang XB, Yan HD, et al
    Metabolic associated fatty liver disease increases coronavirus disease 2019 disease severity in nondiabetic patients.
    J Gastroenterol Hepatol. 2021;36:204-207.
    PubMed     Abstract available
    
    
    
73. LUM JHM, Cheah MCC, Leow WQ, Wan WK, et al
    Clinical profile of non-alcoholic fatty liver disease in nonobese patients.
    J Gastroenterol Hepatol. 2021;36:257-261.
    PubMed     Abstract available
    
    
    
74. GRONBAEK H, Moller HJ, Saliba F, Zeuzem S, et al
    Improved prediction of mortality by combinations of inflammatory markers and standard clinical scores in patients with acute-on-chronic liver failure and acute decompensation.
    J Gastroenterol Hepatol. 2021;36:240-248.
    PubMed     Abstract available
    
    
    December 2020
75. YAMAOKA K, Kodama K, Hiramatsu A, Ando Y, et al
    Extracellular water to total body water ratio obtained by bioelectrical impedance analysis determines the dose intensity of lenvatinib for the treatment of patients with advanced hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2020 Dec 16. doi: 10.1111/jgh.15377.
    PubMed     Abstract available
    
    
    
76. MOCAN T, Nenu I, Craciun R, Sparchez Z, et al
    Treatment of hepatitis C virus infection in patients with hepatocellular carcinoma: truth or dare?
    J Gastroenterol Hepatol. 2020 Dec 16. doi: 10.1111/jgh.15376.
    PubMed     Abstract available
    
    
    
77. TERRA C, Perez R
    Albumin for cirrhotic patients with infections unrelated to spontaneous bacterial peritonitis: A still no answered question.
    J Gastroenterol Hepatol. 2020;35:2290-2291.
    PubMed    
    
    
    November 2020
78. KIM DY, Lee HW, Kang W, Kim GM, et al
    Metabolic activity assessment by 18F-FDG PET in patients with hepatocellular carcinoma undergoing Yttrium-90 TARE.
    J Gastroenterol Hepatol. 2020 Nov 23. doi: 10.1111/jgh.15357.
    PubMed     Abstract available
    
    
    
79. KIM KJ, Lee HW, Seong J
    Combination therapy with anti-TIM3 and radiation improves antitumor efficacy in murine hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2020 Nov 20. doi: 10.1111/jgh.15319.
    PubMed     Abstract available
    
    
    
80. KIM S, Kim KH, Kim BK, Park JY, et al
    Lenvatinib is independently associated with the reduced risk of progressive disease when compared to sorafenib in patients with advanced hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2020 Nov 20. doi: 10.1111/jgh.15355.
    PubMed     Abstract available
    
    
    
81. CRESPO J, Fernandez Carrillo C, Iruzubieta P, Hernandez-Conde M, et al
    MASSIVE IMPACT OF COVID-19 PANDEMIC ON GASTROENTEROLOGY AND HEPATOLOGY DEPARTMENTS AND DOCTORS IN SPAIN.
    J Gastroenterol Hepatol. 2020 Nov 12. doi: 10.1111/jgh.15340.
    PubMed     Abstract available
    
    
    
82. HIRAOKA A, Kumada T, Kariyama K, Tada T, et al
    Clinical importance of muscle volume in lenvatinib for hepatocellular carcinoma: analysis adjusted with inverse probability weighting.
    J Gastroenterol Hepatol. 2020 Nov 10. doi: 10.1111/jgh.15336.
    PubMed     Abstract available
    
    
    
83. CHEN H, Sung JJ
    Potentials of AI in Medical Image Analysis in Gastroenterology and Hepatology.
    J Gastroenterol Hepatol. 2020 Nov 3. doi: 10.1111/jgh.15327.
    PubMed     Abstract available
    
    
    October 2020
84. WANG J, Ning J, Qian X, Zhang T, et al
    Deletion of Golgi protein73 delayed hepatocytes proliferation of mouse in the early stages of liver regeneration.
    J Gastroenterol Hepatol. 2020 Oct 29. doi: 10.1111/jgh.15315.
    PubMed     Abstract available
    
    
    
85. TOSHIMA T, Yoshizumi T, Harada N, Ikegami T, et al
    Hepatobiliary and Pancreatic: A new strategy of endoscopic ultrasonography-guided internal drainage for a refractory hepatic abscess after liver transplantation.
    J Gastroenterol Hepatol. 2020 Oct 7. doi: 10.1111/jgh.15216.
    PubMed    
    
    
    
86. GAO F, Huang JF, Zheng KI, Pan XY, et al
    Development and validation of a novel non-invasive test for diagnosing fibrotic non-alcoholic steatohepatitis in patients with biopsy-proven non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2020;35:1804-1812.
    PubMed     Abstract available
    
    
    
87. WIJARNPREECHA K, Scribani M, Raymond P, Harnois DM, et al
    PNPLA3 gene polymorphism and overall and cardiovascular mortality in the United States.
    J Gastroenterol Hepatol. 2020;35:1789-1794.
    PubMed     Abstract available
    
    
    
88. KITAGATAYA T, Suda G, Nagashima K, Katsurada T, et al
    Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan.
    J Gastroenterol Hepatol. 2020;35:1782-1788.
    PubMed     Abstract available
    
    
    
89. SALMAN AA, Sultan AAEA, Abdallah A, Abdelsalam A, et al
    Effect of weight loss induced by laparoscopic sleeve gastrectomy on liver histology and serum adipokine levels.
    J Gastroenterol Hepatol. 2020;35:1769-1773.
    PubMed     Abstract available
    
    
    
90. YANG J, Sontag D, Gong Y, Minuk GY, et al
    Enhanced Gemcitabine Cytotoxicity with Knockdown of Multidrug Resistance Protein Genes in Human Cholangiocarcinoma Cell Lines.
    J Gastroenterol Hepatol. 2020 Oct 1. doi: 10.1111/jgh.15289.
    PubMed     Abstract available
    
    
    September 2020
91. NAKAJIMA T, Karino Y, Hige S, Suii H, et al
    Factors affecting the recovery of hepatic reserve after sustained virologic response by direct-acting antiviral agents in chronic HCV-infected patients.
    J Gastroenterol Hepatol. 2020 Sep 29. doi: 10.1111/jgh.15280.
    PubMed     Abstract available
    
    
    
92. YOKOYAMA K, Irie M, Tsuchiya N, Yamauchi E, et al
    Irsogladine maleate alters expression of a tight junction protein in portal hypertensive gastropathy.
    J Gastroenterol Hepatol. 2020 Sep 14. doi: 10.1111/jgh.15259.
    PubMed     Abstract available
    
    
    
93. SANDI BB, Leao GS, de Mattos AA, de Mattos AZ, et al
    Long-term albumin administration in patients with cirrhosis and ascites: a meta-analysis of randomized controlled trials.
    J Gastroenterol Hepatol. 2020 Sep 10. doi: 10.1111/jgh.15253.
    PubMed     Abstract available
    
    
    
94. PARK S, Jung J, Cho B, Kim SY, et al
    In reply to Huo et al.: Treating Small Hepatocellular Carcinoma: Stereotactic Body Radiation Therapy Versus Radiofrequency Ablation.
    J Gastroenterol Hepatol. 2020 Sep 9. doi: 10.1111/jgh.15250.
    PubMed    
    
    
    
95. PYO JH, Kim TJ, Lee H, Choi SC, et al
    Proton Pump Inhibitors Use and the Risk of Fatty Liver Disease; A Nationwide Cohort Study.
    J Gastroenterol Hepatol. 2020 Sep 4. doi: 10.1111/jgh.15236.
    PubMed     Abstract available
    
    
    
96. YOU MW, Kim KW, Shim JJ, Pyo J, et al
    Impact of liver-stiffness measurement on hepatocellular carcinoma development in chronic hepatitis C patients treated with direct-acting antivirals: A systematic review and time-to-event meta-analysis.
    J Gastroenterol Hepatol. 2020 Sep 1. doi: 10.1111/jgh.15243.
    PubMed     Abstract available
    
    
    
97. SHIMIZU Y, Tamura T, Kemmochi A, Owada Y, et al
    Oxidative stress and LXR agonist induce hepatocellular carcinoma in NASH model.
    J Gastroenterol Hepatol. 2020 Sep 1. doi: 10.1111/jgh.15239.
    PubMed     Abstract available
    
    
    
98. KOGISO T, Hashimoto E
    Are low triglyceride levels the cause or an outcome of advanced liver fibrosis in elderly patients with nonalcoholic fatty liver disease?
    J Gastroenterol Hepatol. 2020;35:1459-1460.
    PubMed    
    
    
    
99. CHEN TP, Lai M, Lin WY, Huang KC, et al
    Metabolic profiles and fibrosis of nonalcoholic fatty liver disease in the elderly: A community-based study.
    J Gastroenterol Hepatol. 2020;35:1636-1643.
    PubMed     Abstract available
    
    
    
100. ADAMS LA, Roberts SK, Strasser SI, Mahady SE, et al
     Nonalcoholic fatty liver disease burden: Australia, 2019-2030.
     J Gastroenterol Hepatol. 2020;35:1628-1635.
     PubMed     Abstract available
     
     
     August 2020
101. DEL HOYO J, Lopez-Munoz P, Fernandez-de la Varga M, Garrido-Marin A, et al
     Hepatobiliary and Pancreatic: A fatal case of extensive splanchnic vein thrombosis in a patient with Covid-19.
     J Gastroenterol Hepatol. 2020 Aug 24. doi: 10.1111/jgh.15174.
     PubMed    
     
     
     
102. HIRAI M, Kinugasa H, Nouso K, Yamamoto S, et al
     Prediction of the prognosis of advanced hepatocellular carcinoma by TERT promoter mutations in circulating tumor DNA.
     J Gastroenterol Hepatol. 2020 Aug 24. doi: 10.1111/jgh.15227.
     PubMed     Abstract available
     
     
     
103. EFE C, Torgutalp M, Henriksson I, Alalkim F, et al
     Extrahepatic autoimmune diseases in primary biliary cholangitis: prevalence, significance for clinical presentation and disease outcome.
     J Gastroenterol Hepatol. 2020 Aug 13. doi: 10.1111/jgh.15214.
     PubMed     Abstract available
     
     
     
104. CHUAH KH, Lai LL, Vethakkan SR, Nik Mustapha NR, et al
     Liver stiffness measurement in non-alcoholic fatty liver disease: Two is better than one.
     J Gastroenterol Hepatol. 2020;35:1404-1411.
     PubMed     Abstract available
     
     
     
105. SHARMA A, Goel A, Moses V, Keshava SN, et al
     Anticoagulating Budd-Chiari syndrome patients presenting with variceal bleed: A retrospective study.
     J Gastroenterol Hepatol. 2020;35:1397-1403.
     PubMed     Abstract available
     
     
     July 2020
106. HUO TI, Ho SY, Liu PH
     Is CT-enhanced clinical significant portal hypertension surrogate an authentic prognostic predictor for surgical hepatocellular carcinoma?
     J Gastroenterol Hepatol. 2020 Jul 27. doi: 10.1111/jgh.15203.
     PubMed    
     
     
     
107. KHAN A, Maheshwari S, Gupta K, Naseem K, et al
     Rate, Reasons, Predictors, and Burden of Readmissions After Transjugular Intrahepatic Portosystemic Shunt Placement.
     J Gastroenterol Hepatol. 2020 Jul 25. doi: 10.1111/jgh.15194.
     PubMed     Abstract available
     
     
     
108. KIM KS, Kwon HM, Jung KW, Sang BH, et al
     Markedly prolonged QTc interval in end-stage liver disease and risk of 30-day cardiovascular event after liver transplant.
     J Gastroenterol Hepatol. 2020 Jul 13. doi: 10.1111/jgh.15179.
     PubMed     Abstract available
     
     
     
109. CHEN A, Li S, Yao Z, Hu J, et al
     Adjuvant Transarterial Chemoembolization to Sorafenib in Unresectable Hepatocellular Carcinoma: A Meta-Analysis.
     J Gastroenterol Hepatol. 2020 Jul 11. doi: 10.1111/jgh.15180.
     PubMed     Abstract available
     
     
     
110. SHANKER MD, Liu HY, Lee YY, Stuart KA, et al
     Stereotactic radiotherapy for hepatocellular carcinoma: Expanding the multidisciplinary armamentarium.
     J Gastroenterol Hepatol. 2020 Jul 6. doi: 10.1111/jgh.15175.
     PubMed     Abstract available
     
     
     
111. LAUBE R, Sabih AH, Strasser SI, Lim L, et al
     Palliative Care in Hepatocellular Carcinoma.
     J Gastroenterol Hepatol. 2020 Jul 6. doi: 10.1111/jgh.15169.
     PubMed     Abstract available
     
     
     
112. YAMAMURA S, Nakano D, Hashida R, Tsutsumi T, et al
     Patient-reported outcomes in patients with non-alcoholic fatty liver disease: A narrative review of Chronic Liver Disease Questionnaire-non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.
     J Gastroenterol Hepatol. 2020 Jul 6. doi: 10.1111/jgh.15172.
     PubMed     Abstract available
     
     
     
113. FAN J, Wang Q, Luo B, Chen H, et al
     Prevalence of prothrombotic factors in patients with Budd-Chiari syndrome or non-cirrhotic nonmalignant portal vein thrombosis: A hospital-based observational study.
     J Gastroenterol Hepatol. 2020;35:1215-1222.
     PubMed     Abstract available
     
     
     June 2020
114. TANG RSY, Kyaw MH, Teoh AYB, Lui RNS, et al
     EUS guided cyanoacrylate injection to prevent rebleeding in hepatocellular carcinoma patients with variceal hemorrhage.
     J Gastroenterol Hepatol. 2020 Jun 30. doi: 10.1111/jgh.15168.
     PubMed     Abstract available
     
     
     
115. TAN EZ, Lai LL, Vethakkan SR, Nik Mustapha NR, et al
     Modest alcohol intake is not associated with significant hepatic steatosis nor more severe liver disease among patient with diabetes mellitus.
     J Gastroenterol Hepatol. 2020 Jun 24. doi: 10.1111/jgh.15160.
     PubMed     Abstract available
     
     
     
116. BRAHMANIA M, Wiskar K, Walley KR, Celi LA, et al
     Lower household income is associated with an increased risk of hospital readmission in patients with decompensated cirrhosis.
     J Gastroenterol Hepatol. 2020 Jun 20. doi: 10.1111/jgh.15153.
     PubMed     Abstract available
     
     
     
117. SAKAI N, Yoshitomi H, Furukawa K, Takayashiki T, et al
     Outcome of interventional radiology for delayed postoperative hemorrhage in hepatobiliary and pancreatic surgery.
     J Gastroenterol Hepatol. 2020 Jun 11. doi: 10.1111/jgh.15140.
     PubMed     Abstract available
     
     
     
118. CAO DB, Wang YS
     Gastrointestinal: Intrahepatic periportal masses with uncommon computed tomography patterns: Hepatic extramedullary hematopoiesis of primary mylofibrosis.
     J Gastroenterol Hepatol. 2020 Jun 7. doi: 10.1111/jgh.15069.
     PubMed    
     
     
     
119. GURKA MJ, Mack JA, Chi X, DeBoer MD, et al
     Use of Metabolic Syndrome Severity to Assess Treatment with Vitamin-E and Pioglitazone for Non-alcoholic Steatohepatitis.
     J Gastroenterol Hepatol. 2020 Jun 7. doi: 10.1111/jgh.15131.
     PubMed     Abstract available
     
     
     
120. GOMEZ CIFUENTES JD, Sparkman J, Choi K, Sealock RJ, et al
     Regarding: Lui RN, Wong SH, Sanchez-Luna SA, et al. Overview of guidance for endoscopy during the coronavirus disease 2019 pandemic. J Gastroenterol Hepatol. 2020;35(5):749-759. doi:10.1111/jgh.15053.
     J Gastroenterol Hepatol. 2020 Jun 5. doi: 10.1111/jgh.15129.
     PubMed    
     
     
     
121. LEE HW, Ahn SH
     How do genetic variants affect our interpretation of non-invasive tests for non-alcoholic fatty liver disease?
     J Gastroenterol Hepatol. 2020;35:915-916.
     PubMed    
     
     
     
122. SHIN SK, Kim KO, Kim SH, Kwon OS, et al
     Exogenous 8-hydroxydeoxyguanosine ameliorates liver fibrosis through the inhibition of Rac1-NADPH oxidase signaling.
     J Gastroenterol Hepatol. 2020;35:1078-1087.
     PubMed     Abstract available
     
     
     
123. NGUYEN TH, Wardell R, Chitturi S, Teoh N, et al
     When the liver gets stiff, the tough get moving.
     J Gastroenterol Hepatol. 2020;35:953-959.
     PubMed     Abstract available
     
     
     
124. SAWADA K, Hayashi H, Nakajima S, Hasebe T, et al
     Non-alcoholic fatty liver disease is a potential risk factor for liver injury caused by immune checkpoint inhibitor.
     J Gastroenterol Hepatol. 2020;35:1042-1048.
     PubMed     Abstract available
     
     
     
125. LIU WY, Zheng KI, Pan XY, Ma HL, et al
     Effect of PNPLA3 polymorphism on diagnostic performance of various noninvasive markers for diagnosing and staging nonalcoholic fatty liver disease.
     J Gastroenterol Hepatol. 2020;35:1057-1064.
     PubMed     Abstract available
     
     
     
126. CHEN H, He C, Lv Y, Fan J, et al
     Long-term results of variceal bleeding management in 302 patients with chronic extrahepatic portal vein obstruction.
     J Gastroenterol Hepatol. 2020;35:1049-1056.
     PubMed     Abstract available
     
     
     May 2020
127. HUO TI, Liu PH, Ho SY
     Treating small hepatocellular carcinoma: Stereotactic body radiation therapy vs RFA.
     J Gastroenterol Hepatol. 2020 May 31. doi: 10.1111/jgh.15126.
     PubMed    
     
     
     
128. LI Y, He HC, Zhou DL, Liu Q, et al
     Associations between lncRNA-related polymorphisms and hepatocellular carcinoma risk: A two-stage case-control study.
     J Gastroenterol Hepatol. 2020 May 26. doi: 10.1111/jgh.15118.
     PubMed     Abstract available
     
     
     
129. LEE DH, Chung JW, Joo I, Suh KS, et al
     Varices on Computed Tomography Could Predict Survival after Hepatic Resection in Patients with Single Hepatocellular Carcinoma.
     J Gastroenterol Hepatol. 2020 May 26. doi: 10.1111/jgh.15117.
     PubMed     Abstract available
     
     
     
130. XU X, Lei Y, Zhou H, Guo Y, et al
     beta-Arrestin1 involves in hepatocellular carcinoma metastasis via ERK mediated epithelial-mesenchymal transition.
     J Gastroenterol Hepatol. 2020 May 22. doi: 10.1111/jgh.15115.
     PubMed     Abstract available
     
     
     
131. MA KW, So H, Cho DH, Oh JS, et al
     Durability and outcome of EUS-guided hepaticoduodenostomy using a fully covered metal stent for segregated right intrahepatic duct dilatation.
     J Gastroenterol Hepatol. 2020 May 4. doi: 10.1111/jgh.15089.
     PubMed     Abstract available
     
     
     
132. KOBAYASHI T, Kanno K, Nguyen PT, Sugiyama A, et al
     Periostin antisense oligonucleotide prevents hepatic steatosis and fibrosis in a mouse model of nonalcoholic steatohepatitis.
     J Gastroenterol Hepatol. 2020 May 4. doi: 10.1111/jgh.15088.
     PubMed     Abstract available
     
     
     
133. YANG C, Yang H, Deng S, Zhang Y, et al
     Hepatobiliary and Pancreatic: Hepatic cystadenoma mimics hepatic cystic echinococcsis.
     J Gastroenterol Hepatol. 2020 May 3. doi: 10.1111/jgh.15044.
     PubMed    
     
     
     
134. WARRILLOW S, Fisher C, Tibballs H, Bailey M, et al
     Coagulation abnormalities, bleeding, thrombosis, and management of patients with acute liver failure in Australia and New Zealand.
     J Gastroenterol Hepatol. 2020;35:846-854.
     PubMed     Abstract available
     
     
     
135. SINN DH, Kang D, Chang Y, Ryu S, et al
     Non-alcoholic fatty liver disease and the incidence of myocardial infarction: A cohort study.
     J Gastroenterol Hepatol. 2020;35:833-839.
     PubMed     Abstract available
     
     
     April 2020
136. YIP TC, Wong GL, Chan HL, Tse YK, et al
     Elevated testosterone increases risk of hepatocellular carcinoma in men with chronic hepatitis B and diabetes mellitus.
     J Gastroenterol Hepatol. 2020 Apr 28. doi: 10.1111/jgh.15079.
     PubMed     Abstract available
     
     
     
137. TSENG CH, Tseng CM, Wu JL, Hsu YC, et al
     Magnitude of and Prediction for Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Taking Entecavir or Tenofovir Therapy: A Systematic Review.
     J Gastroenterol Hepatol. 2020 Apr 28. doi: 10.1111/jgh.15078.
     PubMed     Abstract available
     
     
     
138. MAZIDI M, Ofori-Asenso R, Kengne AP
     Dietary Patterns Are Associated with Likelihood of Hepatic Steatosis among US Adults.
     J Gastroenterol Hepatol. 2020 Apr 26. doi: 10.1111/jgh.15076.
     PubMed     Abstract available
     
     
     
139. WANG Y, Shen J, Feng S, Liang R, et al
     Hepatic Resection versus Transarterial Chemoembolization in Infiltrative Hepatocellular Carcinoma: A Multicenter Study.
     J Gastroenterol Hepatol. 2020 Apr 4. doi: 10.1111/jgh.15060.
     PubMed     Abstract available
     
     
     
140. OGURA T, Nishioka N, Ueno S, Yamada M, et al
     Guidewire insertion under transluminal cholangioscopy guidance for a hepaticojejunostomy stricture resembling a pinhole (with video).
     J Gastroenterol Hepatol. 2020 Apr 4. doi: 10.1111/jgh.15050.
     PubMed    
     
     
     
141. SHARMA S, Kumar R, Rout G, Gamanagatti SR, et al
     Dabigatran as an oral anticoagulant in patients with Budd-Chiari syndrome post-percutaneous endovascular intervention.
     J Gastroenterol Hepatol. 2020;35:654-662.
     PubMed     Abstract available
     
     
     March 2020
142. KIM JH, Kang SH, Lee M, Choi HS, et al
     Improved Detection of Hepatocellular Carcinoma by Dynamic CT in Cirrhotic Patients With Chronic Hepatitis B: A Multi-Center Study.
     J Gastroenterol Hepatol. 2020 Mar 28. doi: 10.1111/jgh.15046.
     PubMed     Abstract available
     
     
     
143. YE L, Yu Y, Zhao Y
     Icariin-induced miR-875-5p attenuates epithelial-mesenchymal transition by targeting hedgehog signaling in liver fibrosis.
     J Gastroenterol Hepatol. 2020;35:482-491.
     PubMed     Abstract available
     
     
     February 2020
144. KHOO S, Wong VW, Goh GB, Fan J, et al
     Suboptimal treatment of dyslipidemia in patients with nonalcoholic fatty liver disease.
     J Gastroenterol Hepatol. 2020;35:320-325.
     PubMed     Abstract available
     
     
     
145. SAHLMAN P, Nissinen M, Puukka P, Jula A, et al
     Genetic and lifestyle risk factors for advanced liver disease among men and women.
     J Gastroenterol Hepatol. 2020;35:291-298.
     PubMed     Abstract available
     
     
     
146. HIROOKA M, Ochi H, Hiraoka A, Koizumi Y, et al
     Role of severe thrombocytopenia in preventing platelet count recovery in thrombocytopenic patients with chronic liver disease.
     J Gastroenterol Hepatol. 2020;35:299-304.
     PubMed     Abstract available
     
     
     January 2020
147. LEONG WL, Lai LL, Nik Mustapha NR, Vijayananthan A, et al
     Comparing point shear wave elastography (ElastPQ) and transient elastography for diagnosis of fibrosis stage in non-alcoholic fatty liver disease.
     J Gastroenterol Hepatol. 2020;35:135-141.
     PubMed     Abstract available
     
     
     
148. CHUNG GE, Heo NJ, Kim D, Kwak MS, et al
     Association between advanced fibrosis in fatty liver disease and overall mortality based on body fat distribution.
     J Gastroenterol Hepatol. 2020;35:90-96.
     PubMed     Abstract available
     
     
     November 2019
149. JOSHITA S, Yamashita Y, Sugiura A, Uehara T, et al
     Clinical utility of FibroScan as a non-invasive diagnostic test for primary biliary cholangitis.
     J Gastroenterol Hepatol. 2019 Nov 14. doi: 10.1111/jgh.14929.
     PubMed     Abstract available
     
     
     
150. FRENCH J, van der Mei I, Simpson S Jr, Ng J, et al
     Increasing Prevalence of Primary Biliary Cholangitis in Victoria, Australia.
     J Gastroenterol Hepatol. 2019 Nov 6. doi: 10.1111/jgh.14924.
     PubMed     Abstract available
     
     
     
151. TAKANO K, Saeki C, Oikawa T, Hidaka A, et al
     IgM response is a prognostic biomarker of primary biliary cholangitis treated with ursodeoxycholic acid and bezafibrate.
     J Gastroenterol Hepatol. 2019 Nov 1. doi: 10.1111/jgh.14900.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: